159 related articles for article (PubMed ID: 26384210)
1. ALK alteration is a frequent event in aggressive breast cancers.
Siraj AK; Beg S; Jehan Z; Prabhakaran S; Ahmed M; R Hussain A; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
Breast Cancer Res; 2015 Sep; 17():127. PubMed ID: 26384210
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters.
Hashmi AA; Edhi MM; Naqvi H; Khurshid A; Faridi N
Breast J; 2014; 20(6):578-85. PubMed ID: 25219294
[TBL] [Abstract][Full Text] [Related]
3. ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
Bavi P; Jehan Z; Bu R; Prabhakaran S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Al-Halouly T; Sairafi R; Uddin S; Al-Kuraya KS
Br J Cancer; 2013 Nov; 109(10):2735-43. PubMed ID: 24129244
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.
Kim MH; Lee S; Koo JS; Jung KH; Park IH; Jeong J; Kim SI; Park S; Park HS; Park BW; Kim JH; Sohn J
PLoS One; 2015; 10(3):e0120320. PubMed ID: 25803816
[TBL] [Abstract][Full Text] [Related]
5. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
6. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
7. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
8. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
9. A new look at the ALK gene in cancer: copy number gain and amplification.
Zito Marino F; Rocco G; Morabito A; Mignogna C; Intartaglia M; Liguori G; Botti G; Franco R
Expert Rev Anticancer Ther; 2016 May; 16(5):493-502. PubMed ID: 26943457
[TBL] [Abstract][Full Text] [Related]
10. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
[TBL] [Abstract][Full Text] [Related]
11. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
15. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
17. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
[TBL] [Abstract][Full Text] [Related]
19. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
20. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
